ABSTRACT
The last decade has seen a rapid rise in the number of Assisted Reproductive Technology (ART) centers electing to treat patients with blood borne viruses such as HIV, Hepatitis B and C. This chapter sets out the considerations to be given to planning and managing a costeffective, safe and ethically sensitive service and reviews the evidence base for the proposed therapeutic regimes.
